Ginsenoside C-K polymorphic compounds and method for preparing same

Patent metadata

Field	Value
Publication number	US-9670245-B2
Application number	US-201314389357-A
Country	US
Kind code	B2
Filing date	Apr 1, 2013
Priority date	Apr 1, 2012
Publication date	Jun 6, 2017
Grant date	Jun 6, 2017

Abstract

Provided are several types of ginsenoside polymorphic substances and a method for preparing same. In particular, new crystal form A, crystal form B, crystal form C, crystal form E, crystal form F, crystal form I, crystal form K, crystal form L, crystal form M, crystal form N, and crystal form O are involved.

First claim

The invention claimed is:

1. A crystal form A of ginsenoside C-K, characterized by an XRPD pattern comprising peaks at 2θ values of 5.44, 7.06, 8.94, 11.61, 13.70, 14.43, 15.81, 17.22, 17.84, 18.71, and 19.01 degrees, wherein the error range of the 2θ values is ±0.2 degrees.

2. The crystal form A according to claim 1 , wherein the XRPD pattern further comprises peaks at 2θ values of 9.51, 12.28, 16.14, 20.90, 21.90, 25.68, and 27.71 degrees, wherein the error range of the 2θ values is ±0.2 degrees.

3. A method for preparing the crystal form A of ginsenoside C-K according to claim 1 , comprising:
(1) dissolving ginsenoside C-K in 1-methyl-2-pyrrolidone or a mixed solvent consisting of 1-methyl-2-pyrrolidone and acetone;
(2) removing the solvent slowly by evaporation; and
(3) drying the resultant solid under vacuum to obtain the crystal form A of ginsenoside C-K.

4. The crystal form A according to claim 1 , wherein the XRPD pattern is substantially the same as FIG. 1 .

5. The crystal form A according to claim 1 , further characterized by a DSC pattern comprising an endothermic peak at 117±5° C.

6. The crystal form A according to claim 2 , further characterized by a DSC pattern comprising an endothermic peak at 117±5° C.

7. The crystal form A according to claim 4 , further characterized by a DSC pattern comprising an endothermic peak at 117±5° C.

8. A method for preparing the crystal form A of ginsenoside C-K according to claim 1 , comprising:
(1) dissolving ginsenoside C-K in 1-methyl-2-pyrrolidone;
(2) adding an anti-solvent dropwise, wherein the anti-solvent is selected from the group consisting of isopropyl ether, water, and nitromethane; and
(3) after stirring for a while, filtering the resultant suspension, and drying the filter cake under vacuum to obtain the crystal form A of ginsenoside C-K.

Assignees

• Zhejiang Hisun Pharm Co Ltd

Inventors

• Ren Guobin
• Dai Changliang
• Chen Jinyao
• Chen Feng
• Qi Minghui
• Zhu Wenming
• Hong Minghuang
• Bai Hua

Classifications

• C07B2200/13

  Crystalline forms, e.g. polymorphs · CPC title

• C07J17/00 Primary

  Normal steroids containing carbon, hydrogen, halogen or oxygen, having an oxygen-containing hetero ring not condensed with the cyclopenta(a)hydrophenanthrene skeleton (cardanolide, bufanolide C07J19/00) · CPC title

• C07J17/005 Primary

  Glycosides · CPC title